4D Molecular Therapeutics Soars 11.9% on Positive Outlook

On September 4, 2025, 4D Molecular Therapeutics (FDMT) saw a significant pre-market rise of 11.9%, reflecting strong investor sentiment and potential market opportunities.

Analysts have shown a positive outlook on 4D Molecular Therapeutics, with an average rating of "Buy" and a 12-month stock price target of $30.63, indicating a substantial increase from current levels. This optimistic forecast is supported by the company's innovative approach in the biotherapeutics sector, which has garnered attention from investors and industry experts alike.

The company's stock price has been subject to various forecasts, with price targets ranging from $10 to $40. This wide range reflects the high potential and volatility associated with the biotech industry, where breakthroughs can lead to significant gains. The average price target represents a substantial increase, underscoring the confidence in 4D Molecular Therapeutics' future prospects.

4D Molecular Therapeutics' market capitalization stands at $0.28 billion, positioning it as a notable player in the biotech sector. The company's focus on developing innovative biotherapeutics has attracted the attention of major holders, further solidifying its standing in the market.